Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947917 · ClinicalTrials.gov registry record · NA
Axillary Lymph Node Tattoo Marking Study
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT04947917 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT04947917, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study investigates if SpotTM ink can help breast surgeons retrieve sampled lymph node as well as or better than the standard clip and radioseed guidance methods. The names of the novel study intervention involved in this study is: * SpotTM ink tattooing The names of the standard of care study interventions involved in this study are: * Core needle biopsy and/or fine needle aspiration * Surgical Removal of the Lymph Nodes via clip and radioseed guidance
Interventions
- PROCEDURE SpotTM Tattoo Ink
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2023-04-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04947917
The ClinicalTrials.gov registry entry for NCT04947917 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SpotTM Tattoo Ink is the first listed.
NCT04947917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04947917 about?
NCT04947917 is a clinical study titled "Axillary Lymph Node Tattoo Marking Study". This research study investigates if SpotTM ink can help breast surgeons retrieve sampled lymph node as well as or better than the standard clip and radioseed guidance methods. The names of the novel study intervention involved in this study is: * SpotTM ink tattooing The names of the standard of ...
What is the current status of trial NCT04947917?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2021-12-29. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT04947917?
The interventions under investigation include: SpotTM Tattoo Ink (PROCEDURE).
Who is sponsoring clinical trial NCT04947917?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.